
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ABSORICA LD | Sun Pharmaceutical Industries | N-211913 RX | 2019-11-05 | 4 products, RLD, RS |
| ABSORICA | Sun Pharmaceutical Industries | N-021951 RX | 2012-05-25 | 6 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| absorica | New Drug Application | 2018-11-02 |
| absorica absorica ld | New Drug Application | 2023-06-12 |
| accutane | ANDA | 2023-12-20 |
| amnesteem | ANDA | 2024-06-23 |
| claravis | ANDA | 2022-08-31 |
| epuris | Export only | 2024-12-06 |
| isotretinoin | ANDA | 2025-07-22 |
| myorisan | ANDA | 2022-12-19 |
| sotret | 2006-11-07 | |
| zenatane | ANDA | 2025-07-11 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| leukemia | — | D007938 | C95 |
| acne vulgaris | EFO_0003894 | D000152 | L70 |
| neuroblastoma | EFO_0000621 | D009447 | — |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 2 | — | — | — | — | 2 |
| Drug common name | Isotretinoin |
| INN | isotretinoin |
| Description | Isotretinoin is a retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases. It has a role as a keratolytic drug, an antineoplastic agent and a teratogenic agent. It is a conjugate acid of a 13-cis-retinoate. |
| Classification | Small molecule |
| Drug class | retinol derivatives |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1 |
| PDB | — |
| CAS-ID | 4759-48-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL547 |
| ChEBI ID | 6067 |
| PubChem CID | 5282379 |
| DrugBank | DB00982 |
| UNII ID | EH28UP18IF (ChemIDplus, GSRS) |










